Anavex Life Sciences Corp (AVXL)

[kevindenver]

Hmmmm... but is dose dependency really something of concern to discover in a rare disease population like Rett once a safe effective dose is found?

On the PDD front, I was wondering if 2-73 could also be a possible adjunct therapy to counter the drawbacks of Levodopa off-periods.

"In Part III for motor function, ranging from speech to hand movements, posture to gait, 30 out of 34 items showed score gains (88.23%), while five out of seven items (71.42%) improved in MDS-UPDRS Part IV scores for motor complications like dyskinesia (uncontrolled movement) and levodopa treatment “off” periods."